fda decision tirzepatide FDA's creates uncertainty for patients—and leads to a lawsuit tirzepatide removed from shortage list

4.01.26 April report showed MDL growth There were 3,546 pending actions in the GLP-1 RA MDL

Metabolic improvementsincluding reductions in fasting glucose, HbA1c, and triglyceridesoccurred alongside weight loss, indicating broader cardiometabolic benefits

Many patients find that when their nausea is minimized and their energy is stable, they are much more likely to stick with their exercise routines and healthy eating habits

It reflects biology responding to the absence of the drug

The most noticeable weight changes usually appear within the first few months of treatment

The NovoCare savings card can bring eligible commercially-insured patients to $0 to $25 per month, and the NovoCare Pharmacy direct cash program offers Wegovy at about $499 per month for cash-pay patients